secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001213900-25-099529
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed appoints John Bathery to board; director Baldasare to depart at AGM
-------------------------------------------------------------------------

- John Bathery appointed to Board effective Oct 14, 2025; Board expands to six members.
- Bathery has 30+ years pharma experience, currently Head of Global BD at Takeda, led deals exceeding $60B.
- Bryan Baldasare will not stand for re-election at 2025 AGM due to increasing professional obligations; no disagreements.
- Bathery's expertise expected to support INM-901 (Alzheimer's) and INM-089 (AMD) programs toward clinical readiness and partnerships.
- Bathery receives standard non-employee director compensation: $50,000 annual retainer, potential committee fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025099529/0001213900-25-099529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025099529/ea0261537-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-099529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer